Stay updated on FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.

Latest updates to the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange Detected- Added a government operating status notice and a version bump to v3.2.0. - Removed the old version tag v3.1.0.SummaryDifference2%
- Check21 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows Revision: v3.0.2. The Back to Top element has been removed.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check50 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and various locations across multiple countries, while removing outdated location references and certain genetic disease information.SummaryDifference17%
- Check64 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%
Stay in the know with updates to FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.